6: Effect of CD26 on Cord Blood, and Other Means to Enhance Engraftment of Hematopoietic Stem Cells

Hal E. Broxmeyer
2007 Biology of Blood and Marrow Transplantation  
GVHD were marginally lower after HLA matched or mismatched UCB transplants than after allele-matched BM. Notably, leukemia-free survival (LFS) rates at 5 years were comparable between those receiving allele matched BM (38%) and 1 locus high cell dose (41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mismatched UCB. The observed higher LFS rate (60%) after HLA matched UCB transplant requires validation in a larger cohort. These results in LFS are in part explained by differences in risks of
more » ... erences in risks of transplant related mortality (TRM) and relapse between patient populations. Compared to allele-matched BM transplants, TRM was similar in recipients of matched and 1-locus mismatched UCB and higher in recipients of 2-loci mismatched UCB. Conversely, relapse rates were lower in recipients of UCB transplants mismatched at 2-HLA loci. These results are the first to support the use of HLA matched or mismatched UCB grafts with an adequate cell dose as a first line transplant treatment regardless of the availability of a HLA allele-matched BM donor in the setting of acute leukemia in children aged Ͻ16 years.
doi:10.1016/j.bbmt.2007.08.014 fatcat:v5h7byenend4por4au5jxzdbjq